Tumor spheroids and organoids as preclinical model systems

Area of Science:

• Oncology
• Biomedical Engineering
• Drug Development

Background:

• Traditional 2D cell cultures lack the complexity of the in vivo tumor microenvironment.
• Three-dimensional (3D) cancer models, such as spheroids and organoids, are emerging as more physiologically relevant preclinical tools.
• These 3D models facilitate the study of intricate cell-cell and cell-extracellular matrix interactions crucial for cancer progression.

Purpose of the Study:

• To provide an overview of 3D cancer models (spheroids and organoids) as preclinical systems.
• To highlight the advantages of 3D models in studying cancer biology, personalized medicine, and drug delivery.
• To emphasize the role of 3D models in analyzing cancer stem cells (CSCs) and their implications in therapy resistance.

Main Methods:

• Generation of tumor spheroids from single or co-cultured cell lines.
• Derivation of tumor organoids from tumors or cancer stem cells (CSCs).
• Utilizing patient-derived xenografts by transplanting 3D models into immune-deficient mice for in vivo studies.

Main Results:

• 3D cancer models recapitulate key aspects of the tumor microenvironment, including cell-cell interactions and various cell death pathways.
• These models allow for the analysis of genetic variations, CSCs, and the efficacy of therapeutics and nanoparticles.
• Patient-derived xenografts from 3D models provide a platform for in vivo therapeutic testing.

Conclusions:

• 3D cancer models offer superior insights into tumor processes compared to 2D cultures, despite increased handling complexity.
• These advanced models are crucial for personalized medicine, enabling targeted drug delivery and the study of therapy resistance mechanisms.
• 3D spheroids and organoids represent a significant advancement in preclinical cancer research, bridging the gap between in vitro and in vivo studies.